Lifeblood’s Houston MedTech Event
| March 13th
|
Overview:
Thomas Busby will be moderating a panel at Giovanni Lauricella & Lifeblood‘s MedTech event in Houston on March 13th. This one-day intensive crash course is a must-attend for MedTech CEOs and senior executives looking to gain insights on raising capital, setting strategy, initiating clinical trials, working with a Board, and navigating successful exits via M&A. It’s a fantastic opportunity to connect with industry leaders and deepen your knowledge in the MedTech space. Don’t miss out—register soon as spaces are filling up quickly! |
News
A Panic Letter and the Quiet Reset of American Biotech
This article examines the quiet but profound reset underway in U.S. biotech, triggered by a rare combination of forces: delayed or reduced federal funding, large pharma cutting mid-stage partnerships, and venture capital pulling back as exits evaporate. Based on insights from Dr. Stanislav Glezer, it reveals a market splitting in two — with capital chasing late-stage and very early assets while Phase 1–2 companies are stranded in the middle. The piece also exposes how government uncertainty, shrinking NIH support, and overlooked patient-behavior realities are forcing founders to rethink their entire company lifecycle. In today’s environment, survival requires new strategies, new geographies, and a deeper understanding of human factors that no protocol can fix.
Read MoreResources
Outcome Capital Life Science Market Pulse, October 2025
Outcome Capital Life Science Market Pulse October 2025 Click to view our LifeSciences Pulse Newsletter
DownloadContact Us for More Information
Would you like to learn more about working with Outcome Capital or discuss your specific needs?
© Outcome Capital 2025. Member of Financial Industry Regulatory Authority (FINRA) and the Securities Investment Protection Corporation (SIPC). Check the background of this firm on FINRA’s BrokerCheck.
Outcome Capital and Outcome Life Sciences are affiliates of Outcome Holdings, LLC
Business Continuity Plan | Privacy Policy | Regulation Best Interest
